title: A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria.
abstract: OBJECTIVE
  To obtain comprehensive pharmacokinetic and pharmacodynamic data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following i.v. and oral administration of ARTS to patients with acute, uncomplicated falciparum malaria.
  
  
  METHODS
  Twenty-six Vietnamese patients with falciparum malaria were randomized to receive either i.v. ARTS (120 mg; group 1) or oral ARTS (100 mg; group 2), with the alternative preparation given 8 h later in an open crossover design. Mefloquine (750 mg) was administered at 24 h. Plasma concentrations of ARTS and DHA were determined by h.p.l.c. assay. Pharmacokinetic parameters were calculated by non-compartmental methods. The time to 50% parasite clearance (PCT50) was calculated by linear interpolation of parasite density determinations. Linear least squares and multiple linear regression analyses were used to evaluate pharmacokinetic-pharmacodynamic relationships.
  
  
  RESULTS
  Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1). The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1). Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min. Overall, the PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, respectively. There was no correlation between PCT50 or FCT and AUC, Cmax or MRT for DHA.
  
  
  CONCLUSIONS
  Despite rapid clearance of ARTS and DHA in patients with uncomplicated falciparum malaria, prompt parasite and fever clearance were achieved. High relative bioavailability of DHA following oral ARTS administration, and clinical outcomes comparable with those after i.v. ARTS, support the use of the oral formulation in the primary care setting.
authors.affiliation: Department of Medicine, University of Western Australia, Fremantle Hospital.
authors.forename: K T
authors.initials: KT
authors.lastname: Batty
authors.forename: L T
authors.initials: LT
authors.lastname: Thu
authors.forename: T M
authors.initials: TM
authors.lastname: Davis
authors.forename: K F
authors.initials: KF
authors.lastname: Ilett
authors.forename: T X
authors.initials: TX
authors.lastname: Mai
authors.forename: N C
authors.initials: NC
authors.lastname: Hung
authors.forename: N P
authors.initials: NP
authors.lastname: Tien
authors.forename: S M
authors.initials: SM
authors.lastname: Powell
authors.forename: H V
authors.initials: HV
authors.lastname: Thien
authors.forename: T Q
authors.initials: TQ
authors.lastname: Binh
authors.forename: N V
authors.initials: NV
authors.lastname: Kim
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D037621:Artemisinins; D000077332:Artesunate; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D012016:Reference Values; D012717:Sesquiterpenes / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013997:Time Factors; D014744:Vietnam / Q000453:epidemiology
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D000077332:Artesunate; C039060:artenimol